Bayer Opens New Research & Innovation Center in Boston-Cambridge Demonstrating Its Commitment to Precision Oncology

• New precision molecular oncology research center to drive development of novel targeted cancer therapies for people with unmet medical needs
• Strategic investment of $140M USD to expand presence in leading center of biotech innovation at Kendall Square in Cambridge
• Center will foster close collaboration with scientists and enhance global network of academic, hospital and industry partners located in Boston scientific hub

Bayer AG announced today the opening of its new Research and Innovation Center at Kendall Square in Boston-Cambridge, Massachusetts (U.S.A.), expanding the company’s footprint into one of the world’s most innovative pharmaceutical research and development locations. Representing a total $140M USD investment into the area, Bayer’s 62,100-square-foot facility houses a new center of precision molecular oncology research equipped with state-of-the-art laboratories and offices for the development of novel targeted cancer therapies for patients. In addition, the center comprises a newly established research team focused on leveraging chemical biology techniques to further propel the company’s oncology drug development process.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628006207/en/

Bayer’s new Research Center is located in the top two floors. © Danny Krzewski

“Our new Bayer research and innovation center at Kendall Square is part of our strategy to be at the forefront of scientific discovery and breakthrough innovation for better patient healthcare,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division. “Being part of this unique innovation ecosystem will support our teams in creating breakthrough innovations for patients together with the experts here.”

“Bayer is undergoing significant growth in the United States in both research and development and our commercial operations,” said Sebastian Guth, Ph.D., President of Bayer Pharmaceuticals, Americas Region. “The opening of our new precision molecular oncology research center in Kendall Square reflects the deep commitment Bayer is making to scale our oncology presence in the United States. It also builds on collaborations already in place in Boston in cardiovascular, another key area of focus for Bayer, with our with joint laboratories in precision cardiology with the Broad Institute of MIT and Harvard.”

Spanning across two floors, the new center currently provides space for 100 employees, while the company is prepared to fill an additional 50 roles in the coming months. It is designed to enhance the collaboration between Bayer research and development, its internal partners such as BlueRock Therapeutics, Asklepios BioPharmaceutical (AskBio) and Vividion Therapeutics, as well as external partners to accelerate the development of transformative treatments for patients. In addition to the new center at Kendall Square in Cambridge, Bayer has also established strategic research collaborations with top scientific partners in Boston, including joint laboratories in the areas of lung disease with Brigham and Women’s Hospital and Massachusetts General Hospital and precision cardiology with the Broad Institute of MIT and Harvard.

The Research and Innovation Center also marks a strategic investment into Bayer’s oncology innovation to transform healthcare for people living with cancer worldwide, and at the same time to, ensure sustainable long-term growth for the company. Striving to become a top 10 oncology company by 2030, Bayer is investing a significant portion of its global R&D budget toward oncology. The new precision molecular oncology research center will drive the development of targeted next-generation cancer therapies, including efforts to help people living with cancer benefit from molecular tests and targeted treatments through biomarker testing.

Bayer has a 160-year track record of delivering scientific innovation for patients in areas of high medical need and has long embraced external innovation and partnering. Since 2020, Bayer has secured more than 40 transactions in business development and licensing and has invested $1.2B USD in innovative healthcare companies through Leaps by Bayer. The new center is expected to play a role for future partnering investments and collaborations.

With this new center, Bayer is expanding its operations in the leading life sciences cluster worldwide. Boston-Cambridge is home to approximately 1,000 biotechnology companies, with Kendall Square being the center of pharmaceutical innovation on the East Coast of the USA. The company is now present in four of the largest biotechnology hubs in the United States - Boston, San Francisco, San Diego and Research Triangle Park, NC.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.

Find more information at https://pharma.bayer.com/

Follow us on Facebook: http://www.facebook.com/bayer

Follow us on Twitter: @BayerPharma

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220628006207/en/